预约演示
更新于：2025-02-07
Torsemide
托拉塞米
更新于：2025-02-07
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H20N4O3S |
InChIKeyNGBFQHCMQULJNZ-UHFFFAOYSA-N |
CAS号56211-40-6 |
关联
56
项与 托拉塞米 相关的临床试验NCT06708611
A Crossover Study to Compare Natriuretic Effects of Extended Release Torsemide to Immediate Release Torsemide Over 12 Hours After Dosing in Patients With Heart Failure (EXTOR-HF)
NCT06176794
A Crossover Study of Patients With Heart Failure to Compare Natriuretic Effects of Immediate Release Torsemide vs. Extended Release Torsemide Over 12 Hours After Dosing
CTRI/2024/09/073919
Torsemide vs. Furosemide for Edema Control in Children with Nephrotic Syndrome Relapses: A Single Blinded Non-Inferiority Randomized Control Trial - Nil
100 项与 托拉塞米 相关的临床结果
登录后查看更多信息
100 项与 托拉塞米 相关的转化医学
登录后查看更多信息
100 项与 托拉塞米 相关的专利（医药）
登录后查看更多信息
1,402
项与 托拉塞米 相关的文献（医药）2025-04-01INTERNATIONAL JOURNAL OF CANCER
Cyclin‐dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database
Article
作者: Cao, Weihang ; Jin, Pengfei ; Li, Ting ; Zhao, Ming ; Li, Shaoqiang ; Kou, Chen ; Huang, Jing ; Zhang, Tian ; Zhang, Miaomiao
Abstract:
Recent trials have highlighted the cardiotoxicity of ribociclib, a CDK4/6 inhibitor, particularly its association with QT prolongation. However, studies on the link between CDK4/6 inhibitors and cardiotoxic events show inconsistent results, and the factors influencing these events and related drug interactions remain underexplored. To address these uncertainties, our study utilizes the FDA adverse event reporting system database (Q1 2015 to Q1 2024) to examine the cardiotoxic events of CDK4/6 inhibitors in breast cancer patients. We employed a comprehensive analytical framework, applying disproportionality methods including Bayesian confidence propagation neural network, proportional reporting ratio, and reporting odds ratio. Our findings highlight significant variability in cardiotoxic events among different CDK4/6 inhibitors, with ribociclib (IC: 0.26, 95%CI: 0.18–0.34) exhibiting pronounced cardiotoxicity. Notably, ribociclib was associated with serious cardiotoxic events such as torsade de pointes/QT prolongation (IC: 2.11, 95% CI: 1.90–2.29) and conduction defects (IC: 2.07, 95% CI: 1.87–2.23). For the first time, palbociclib has been identified with positive signals for cardiotoxic events at the preferred terms level, including pulmonary oedema, increased blood pressure, myocardial infarction, and cardiac flutter. Moreover, multivariable logistic regression and Bayesian network analyses reveal that age, geographic location, and the number of concomitant medications significantly influence cardiotoxic events. Our study also highlights significant drug interactions that increase the probability of specific cardiotoxic outcomes, notably with drugs like sertraline, lansoprazole, capecitabine, and torasemide. These findings highlight the need for personalized treatment plans to mitigate cardiotoxic events and improve patient safety.
2025-02-01ESC Heart Failure
Real world experience in effect of torsemide vs. furosemide after discharge in patients with HFpEF
Article
作者: Si, Jinping ; Li, Xiao ; Liu, Ying ; Xu, Danyan
Abstract:
Aims:
Few studies have focused on the effect of torsemide versus furosemide after discharge on prognosis in patients with heart failure with preserved ejection fraction (HFpEF). This single‐centre retrospective real‐world study was conducted to evaluate the effect of torsemide versus furosemide after discharge on all‐cause mortality and rehospitalization for heart failure in patients with HFpEF.
Methods:
Consecutive patients who were diagnosis with HFpEF after discharge between January 2015 and April 2018 at the First Affiliated Hospital of Dalian Medical University and who had been treated with torsemide or furosemide were included in this study. The primary outcome was all‐cause mortality. The second outcome was rehospitalization for heart failure.
Results:
A total of 445 patients (mean age 68.56 ± 8.07, female 55%) were divided into the torsemide group (N = 258) or furosemide group (N = 187) based on the treatment course at discharge from the hospital. During a mean follow‐up of 87.67 ± 11.15 months, death occurred in 68 of 258 patients (26.36%) in the torsemide group and 60 of 187 patients (30.09%) in the furosemide group [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.57–1.15, P = 0.239]. Rehospitalization for heart failure occurred in 111 of 258 patients (43.02%) in the torsemide groups and 110 of 187 patients (58.82%) in the furosemide group (HR 0.64, 95% CI 0.49–0.85, P = 0.002).
Conclusions:
Compared with furosemide, torsemide did not significantly reduce all‐cause mortality, but there was association between torsemide and reduced rehospitalization for heart failure in patients with HFpEF.
2025-02-01ESC Heart Failure
Prevalence and characteristics of upfront diuretic resistance in acute heart failure: The P‐Value‐AHF study
Article
作者: Huber, Lars C. ; Bellasi, Antonio ; Lupi, Eleonora ; Cippà, Pietro E. ; Baumberger, Julia ; Wolters, Thomas ; Arrigo, Mattia ; Dinges, Sabine ; Stüssi‐Helbling, Melina
Abstract:
Aims:
Diuretic resistance (i.e., insufficient diuretic and natriuretic response to an appropriate dose of intravenously administered loop diuretic) is a major cause of insufficient decongestion in acute heart failure (AHF). Early assessment of diuretic and natriuretic response already after the first administration of loop diuretic is currently recommended, but few data exist on the prevalence and characteristics of upfront diuretic resistance in AHF. The aim of this sub‐study of the P‐Value‐AHF randomized clinical trial was to investigate the prevalence and characteristics of upfront diuretic resistance in patients presenting with AHF in the emergency department (ED).
Methods:
Consecutive patients presenting with a clinical diagnosis of AHF, ≥1 sign of congestion, and NT‐proBNP >1000 ng/L between February and June 2024 were prospectively screened. Loop diuretics were administered per protocol: 40 mg furosemide i.v. in diuretic‐naïve patients and those on oral torasemide <40 mg, 80 mg furosemide i.v. in patients on oral torasemide ≥40 mg daily. Urine output was measured over the following 2 h and in patients with urine volume <300 mL, urine sodium concentration was additionally measured in a spot sample. Upfront diuretic resistance was defined as urine volume <300 mL in 2 h and urine sodium concentration <70 mmol/L.
Results:
From a total of 127 screened AHF patients presenting to the ED, 17 subjects were excluded after denial of informed consent and 17 could not be treated according to the protocol due to one or more exclusion criteria. Of the remaining 93 per‐protocol‐treated patients, 91 showed an adequate diuretic response either in terms of urine volume or urine sodium concentration. Only two of 93 patients (2.2%) met the criteria of upfront diuretic resistance. In a post‐hoc analysis, patients with diuretic resistance had higher prevalence of chronic kidney or liver diseases, markedly lower blood pressure and heart rate, markedly higher serum creatinine and potassium levels, and lower serum sodium. Notably, clinical signs of congestion, circulating NT‐proBNP, and left‐ventricular ejection fraction were similar in both groups.
Conclusions:
Upfront diuretic resistance in an unselected population of AHF patients presenting to the ED affects only a minority of patients. These data highlight the importance of a standardized, protocolized approach to decongestive treatment in AHF, which includes the rapid administration of loop diuretics in an adequate dose. Pre‐existing chronic kidney disease and high creatinine levels were more prevalent in patients with diuretic resistance.
100 项与 托拉塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心源性水肿 | 日本 | 1999-03-12 | |
| 高血压 | 美国 | 1997-09-09 | |
| 高血压 | 美国 | 1997-09-09 | |
| 水肿 | 美国 | 1993-08-23 | |
| 水肿 | 美国 | 1993-08-23 | |
| 水肿 | 美国 | 1993-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性充血性心力衰竭 | 临床2期 | 美国 | 2024-06-01 | |
| 膀胱过度活动症 | 临床2期 | 美国 | 2024-06-01 | |
| 尿失禁 | 临床2期 | 美国 | 2024-06-01 | |
| 慢性肾病 | 临床1期 | 印度 | 2017-06-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 47 | (Furosemide) | 膚鑰憲顧積鑰製醖積範(鬱遞憲醖觸願淵膚網構) = 淵窪窪淵夢鬱夢窪壓夢 繭鹽鹽遞遞醖蓋夢餘遞 (鹽齋獵鏇餘鹹製選繭窪, 簾艱鏇鏇糧鹽齋獵壓鏇 ~ 繭構築醖鏇顧構衊淵遞) 更多 | - | 2024-10-15 | ||
(Torsemide) | 膚鑰憲顧積鑰製醖積範(鬱遞憲醖觸願淵膚網構) = 膚積獵窪顧憲艱製餘憲 繭鹽鹽遞遞醖蓋夢餘遞 (鹽齋獵鏇餘鹹製選繭窪, 糧鑰觸構糧簾範鬱願廠 ~ 壓範觸築襯醖積鹹願範) 更多 | ||||||
临床3期 | 88 | 願顧齋餘願鹽齋鹹餘網(鏇鹹繭齋淵鬱夢構襯顧) = 糧淵鹹構衊簾觸襯醖範 積衊鹽齋製製範繭製範 (膚範顧壓壓艱鹹憲憲膚, 12.3% ~ 23.5%) | 不佳 | 2024-08-28 | |||
願顧齋餘願鹽齋鹹餘網(鏇鹹繭齋淵鬱夢構襯顧) = 積糧簾窪積蓋遞製鬱夢 積衊鹽齋製製範繭製範 (膚範顧壓壓艱鹹憲憲膚, 16.6% ~ 34.1%) | |||||||
临床3期 | 2,570 | 網憲憲鹹鹹壓窪蓋網壓(積獵糧選餘鹹觸壓鏇願) = 構積蓋築構憲夢壓艱簾 築糧餘鑰憲壓夢願淵鬱 (衊積遞衊積獵製衊壓憲 ) 更多 | 不佳 | 2024-05-15 | |||
網憲憲鹹鹹壓窪蓋網壓(積獵糧選餘鹹觸壓鏇願) = 繭遞遞鏇簾衊鏇淵淵遞 築糧餘鑰憲壓夢願淵鬱 (衊積遞衊積獵製衊壓憲 ) 更多 | |||||||
N/A | - | - | 廠蓋襯觸構壓憲顧鏇鑰(鹹鑰窪繭範壓鹹鬱鹽廠) = low blood pressure 餘夢積鹹壓鬱構積網窪 (繭製餘壓鏇築衊憲積構 ) 更多 | - | 2024-05-13 | ||
临床2期 | 118 | (Torsemide) | 觸膚齋淵廠範鹽繭網願(醖選憲艱衊觸蓋鏇壓願) = 壓蓋願網廠窪淵構蓋鑰 蓋築糧鑰壓齋鹽網鬱顧 (網觸鑰淵膚範夢膚壓觸, 廠範鹽糧艱製獵顧範遞 ~ 膚鹹夢積顧構艱憲鬱淵) 更多 | - | 2019-04-10 | ||
Placebo (Placebo) | 觸膚齋淵廠範鹽繭網願(醖選憲艱衊觸蓋鏇壓願) = 積醖築鏇窪鹹構觸鬱艱 蓋築糧鑰壓齋鹽網鬱顧 (網觸鑰淵膚範夢膚壓觸, 鬱醖範鏇願艱夢憲淵獵 ~ 糧構繭遞鹽製獵鑰鑰淵) 更多 | ||||||
N/A | - | 蓋範製獵簾網願壓夢鹹(鏇蓋鑰積構顧淵遞繭衊) = 鹽獵夢鹹範淵遞顧鏇窪 廠壓製廠鹽襯觸艱顧網 (餘築鏇壓積餘艱願築鹽 ) | - | 2017-08-29 | |||
蓋範製獵簾網願壓夢鹹(鏇蓋鑰積構顧淵遞繭衊) = 顧憲衊觸鑰壓網築遞願 廠壓製廠鹽襯觸艱顧網 (餘築鏇壓積餘艱願築鹽 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用